Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

C4X Discovery

- PMLiVE

EMA says there is ‘no indication’ AZ/Oxford’s COVID-19 vaccine causes blood clots

Agency’s safety committee added vaccine’s benefits continue to outweigh risks

- PMLiVE

Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s

Country's Health Ministry also recommended extending gap between doses to 12 weeks

- PMLiVE

First shipments of AZ/Oxford COVID-19 vaccine sent through COVAX

First COVAX shipments of vaccine dispatched to Ghana and Cote D’Ivoire

- PMLiVE

UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people

Data suggests vaccine is 80% effective at preventing hospitalisations in over-80s

- PMLiVE

AZ sells stake in Moderna for around $1.2bn

As Moderna expects COVID-19 vaccine sales to reach $18.4bn this year

- PMLiVE

AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population

Detailed results from the NAVIGATOR trial presented at virtual AAAAI meeting

- PMLiVE

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

Immunotherapy failed to hit primary endpoint in phase 3 DANUBE trial last year

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

- PMLiVE

Three strategies for managing loss of exclusivity successfully

Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.

Blue Latitude Health

- PMLiVE

WHO grants emergency use listing for AZ/Oxford University’s COVID-19 vaccine

The emergency use listing authorises the use of the vaccine in all adults, including over-65s

- PMLiVE

AZ/Oxford University’s COVID-19 vaccine to be evaluated in children and young adults

First study to assess the safety and immune response of the vaccine in children

- PMLiVE

AZ forecasts growth in 2021 after revenues surge in Q4

Most recent quarter is first 'for many years' in which product sales were in excess of $7bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links